A SkeleTal Muscle Recovery Intervention with Dietary Protein in Heart Failure

Last updated: December 12, 2024
Sponsor: Tufts Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Heart Failure

Myasthenia Gravis (Chronic Weakness)

Chest Pain

Treatment

Ensure Original

Ensure Max Protein

Clinical Study ID

NCT05627440
STUDY00003095
1R01HL167113-01
  • Ages 18-100
  • All Genders

Study Summary

Severe skeletal wasting and catabolic weight loss are highly common among patients with heart failure with reduced ejection fraction (HFrEF). This prospective randomized controlled trial will compare changes in the muscle mass in the arms and the legs (appendicular lean mass) in patients with HFrEF randomized between 3 groups of no, low- or high-dose protein supplementation. The dietary protein supplementation will be Ensure(R) products manufactured by Abbott Nutrition. The Investigators hypothesize that skeletal muscle wasting in HFrEF is promoted by neurohumoral activation of catabolic metabolism (such as GDF-15 and ActRII pathways) and can be at least partially reversed by increased dietary protein intake. It is anticipated that this study will determine whether dietary protein supplementation helps to prevent muscle wasting and will advance understanding of the GDF-15 and ActRII muscle wasting pathways.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Left ventricular ejection fraction (LVEF) ≤40%, New York Heart Association (NHYA)class II to IV symptoms or N-terminal pro B-natriuretic peptide (NT-proBNP) >300pg/mL

  2. Age 18 years to 100 years, inclusive

  3. Receiving guideline-directed medical therapy (GDMT), unless contraindicated or nottolerated

  4. Any of the following markers of severe HF within prior 12 months: i) Inotropictherapy; ii) 1 or more HF hospitalizations; iii) LVEF ≤25%; iv) Peak oxygenconsumption (VO2) <50% predicted or ≤16 mL/kg/min; v) 6-minute walk distance <300meters; vi) Unintentional weight loss >5% of bodyweight over the past year; vii)Moderate or severe muscle wasting on physical examination; viii) NT-proBNP ≥900pg/mL

Exclusion

Exclusion Criteria:

  1. Pregnancy, planning to become pregnant, or women of reproductive potential unwillingto complete pre-DXA urine pregnancy test before first DXA or randomization

  2. History of left ventricular assist device (LVAD), heart transplantation, orestimated glomerular filtration rate (eGFR) <20 mL/min/1.73 m2

  3. An identified clinical disorder associated with skeletal muscle weakness/wasting (e.g., muscular dystrophy, mitochondrial disorder, active cancer, modified Rankinscore greater or equal to 4 post-stroke)

  4. Milk allergy, protein allergy, lactose intolerance, and galactosemia

  5. Weight ≥350 pounds and/or BMI ≥40 kg/m2

Study Design

Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Ensure Original
Phase:
Study Start date:
April 24, 2023
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • Tufts Medical Center

    Boston, Massachusetts 02111
    United States

    Active - Recruiting

  • Cleveland Clinic

    Cleveland, Ohio 44195
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.